BioXcel Therapeutics(BTAI) - 2024 Q4 - Annual Results

Exhibit 99.1 BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI in the at- home setting Strengthened cash position to advance BXCL501 program ...